

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial

Il Suk Sohn¹ · Chong-Jin Kim¹ · Byung-Hee Oh² · Taek-Jong Hong³ · Chang-Gyu Park⁴ · Byung-Soo Kim⁵ · Woo-Baek Chung⁶ · For the Investigators

Published online: 18 March 2016
© Springer International Publishing Switzerland 2016

Erratum to: Am J Cardiovasc Drugs DOI 10.1007/s40256-015-0156-x

Errors have subsequently been identified in the original publication, and the following corrections should be noted:

Abstract, Results section, lines 9–11 which previously read:

After 8 weeks of double-blind treatment, the changes in msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ group and -4.23 (7.41) mmHg in the OM/HCTZ group (both $p < 0.0001$ vs. baseline; $p < 0.0001$ between groups).

Should read:

After 8 weeks of double-blind treatment, the changes in msDBP were -11.39 (8.34) mmHg in the OM/AML/HCTZ group and -5.74 (9.22) mmHg in the OM/HCTZ

group (both $p < 0.0001$ vs. baseline; $p < 0.0001$ between groups).

Results, Section 3.2 Efficacy, para 1, lines 2–3 which previously read:

After 8 weeks of double-blind treatment, the changes in msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ group and -4.23 (7.41) mmHg in the OM/HCTZ group (both $p < 0.0001$ vs. baseline; $p < 0.0001$ between groups; Fig. 2a).

Should read:

After 8 weeks of double-blind treatment, the changes in msDBP were -11.39 (8.34) mmHg in the OM/AML/HCTZ group and -5.74 (9.22) mmHg in the OM/HCTZ group (both $p < 0.0001$ vs. baseline; $p < 0.0001$ between groups; Fig. 2a).

Results, Section 3.2 Efficacy, para 2, lines 2–5 which previously read:

The changes in msDBP and msSBP from randomization to after 4 weeks of treatment were -11.39 (8.34) mmHg and -14.75 (12.50) mmHg, respectively, in the OM/AML/HCTZ group (both $p < 0.0001$ vs. baseline) and -5.74 (9.22) mmHg and -7.93 (11.99) mmHg, respectively, in the OM/HCTZ group (both $p < 0.0001$ vs. baseline; both $p < 0.0001$ between groups; Fig. 2).

Should read:

...The changes in msDBP and msSBP from randomization to after 4 weeks of treatment were -9.50 (8.46) mmHg and -14.75 (12.50) mmHg, respectively, in the OM/AML/HCTZ group (both $p < 0.0001$ vs. baseline) and -4.23 (7.41) mmHg and -7.93 (11.99) mmHg, respectively, in the OM/HCTZ group (both $p < 0.0001$ vs. baseline; both $p < 0.0001$ between groups; Fig. 2).

The online version of the original article can be found under doi:[10.1007/s40256-015-0156-x](https://doi.org/10.1007/s40256-015-0156-x).

✉ Byung-Hee Oh
ohbhmed@snu.ac.kr

- ¹ Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea
- ² Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro(28 Yongondong), Jongno-gu, Seoul 110-744, Republic of Korea
- ³ Pusan National University Hospital, Busan, Republic of Korea
- ⁴ Korea University Guro Hospital, Seoul, Republic of Korea
- ⁵ Daedong Hospital, Busan, Republic of Korea
- ⁶ Yeouido St. Mary's Hospital of the Catholic University of Korea, Seoul, Republic of Korea